225 related articles for article (PubMed ID: 10736497)
21. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Stark G; MacDonald R; Mulrow C; Lau J
Cochrane Database Syst Rev; 2000; (2):CD001423. PubMed ID: 10796790
[TBL] [Abstract][Full Text] [Related]
22. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens.
Levin RM; Das AK
Urol Res; 2000 Jun; 28(3):201-9. PubMed ID: 10929430
[TBL] [Abstract][Full Text] [Related]
23. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
Amdii RE; Al' Shukri AS
Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
[TBL] [Abstract][Full Text] [Related]
24. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.
Ishani A; MacDonald R; Nelson D; Rutks I; Wilt TJ
Am J Med; 2000 Dec; 109(8):654-64. PubMed ID: 11099686
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
Stepanov VN; Siniakova LA; Sarrazin B; Raynaud JP
Adv Ther; 1999; 16(5):231-41. PubMed ID: 10915398
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
Debruyne F; Boyle P; Calais da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman C
Prog Urol; 2004 Jun; 14(3):326-31. PubMed ID: 15373174
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.
Debruyne F; Boyle P; Calais Da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman CC
Eur Urol; 2004 Jun; 45(6):773-9; disucssion 779-80. PubMed ID: 15149751
[TBL] [Abstract][Full Text] [Related]
28. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
29. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.
Willetts KE; Clements MS; Champion S; Ehsman S; Eden JA
BJU Int; 2003 Aug; 92(3):267-70. PubMed ID: 12887481
[TBL] [Abstract][Full Text] [Related]
30. [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon].
Sivkov AV; Kudriavtsev IuV; Medvedev AA; Razumov SV; Kochetov SA
Urologiia; 2004; (5):10-6. PubMed ID: 15560155
[TBL] [Abstract][Full Text] [Related]
31. [Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens "Pierre Fabre Medicament)].
Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
Urologiia; 2002; (1):23-5. PubMed ID: 11877967
[TBL] [Abstract][Full Text] [Related]
32. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
[TBL] [Abstract][Full Text] [Related]
33. [The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia].
Pytel' IuA; Lopatkin NA; Gorilovskiĭ LM; Vinarov AZ; Sivkov AV; Medvedev AA
Urologiia; 2004; (2):3-7. PubMed ID: 15114742
[TBL] [Abstract][Full Text] [Related]
34. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
Perry R; Milligan G; Anderson P; Gillon A; White M
Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
[TBL] [Abstract][Full Text] [Related]
35. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW; Donnelly F; Ross M; Habib FK
Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
[TBL] [Abstract][Full Text] [Related]
36. [Alternative therapy of benign prostatic hypertrophy--Permixon (Capistan)].
Hanus M; Matousková M
Rozhl Chir; 1993 Feb; 72(2):75-9. PubMed ID: 7692609
[TBL] [Abstract][Full Text] [Related]
37. [Permixon in the treatment of benign prostatic hyperplasia].
Gorilovskiĭ LM
Ter Arkh; 1995; 67(8):62-4. PubMed ID: 7482341
[No Abstract] [Full Text] [Related]
38. Comment on the appropriateness of The Prostate publishing a trial comparing Permixon to finasteride without a placebo control group.
Gillenwater JY
Prostate; 1998 Nov; 37(3):194. PubMed ID: 9792137
[No Abstract] [Full Text] [Related]
39. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.
Vela-Navarrete R; Escribano-Burgos M; Farré AL; García-Cardoso J; Manzarbeitia F; Carrasco C
J Urol; 2005 Feb; 173(2):507-10. PubMed ID: 15643230
[TBL] [Abstract][Full Text] [Related]
40. Phytotherapy for benign prostatic hyperplasia.
Gerber GS
Curr Urol Rep; 2002 Aug; 3(4):285-91. PubMed ID: 12149159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
